| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Multiple targets including nicotinic acid receptors and serotonin receptors. Nicotredole, as a combination of nicotinic acid and tryptamine, may interact with nicotinic acid receptors (GPR109A) and serotonin receptors (5-HT receptors). Nicotinic acid is a ligand for GPR109A, a G protein-coupled receptor involved in lipid metabolism. Tryptamine derivatives are known to interact with serotonin receptors, particularly 5-HT₂ and 5-HT₃ receptors. The compound's biological effects may be mediated through these receptor systems.
|
|---|---|
| ln Vitro |
In vitro prostaglandin synthetase activity is inhibited by nicotinedole[1].
In vitro activity data for nicotredole are limited. As a research compound combining nicotinic acid and tryptamine moieties, it may exhibit activities related to both components. Nicotinic acid is known to activate GPR109A, leading to inhibition of lipolysis and reduction of free fatty acid levels. Tryptamine derivatives may have serotonergic effects. The compound's specific in vitro activities would depend on the concentrations tested and the assay systems used. Further studies are needed to characterize its activity profile. |
| ln Vivo |
Rat paw oedema produced by carrageenin responds to intrathecal nicotine]1. In addition to producing analgesic effects, nicotredole reverses pyrogen-induced hyperthermia in rats, increases the duration of hexobarbital sleep in rats, and reduces locomotor activity in both rats and mice[1]. For male rats and male mice, the LD50s of itotrezole (ip) are 1260 mg/kg and 1980 mg/kg, respectively[1]. For male rats and male mice, the LD50s of nicotredole (po) are 8.5 g/kg and 9.3 g/kg, respectively[1]. Nicotredole (25 mg/kg; po or ip) has rapid elimination (t1/2=55.72-74.52 min) and absorption (t1/2=4.92-17.5 min). After 30 min, it can achieve its Cmax (11–13 μg/cm3), and its AUC values fall between 21.40 and 27.30 (μg·h/cm3)[2].
In vivo studies of nicotredole are limited. As a research compound, it may be evaluated for its effects on lipid metabolism, neurological function, or other endpoints. Nicotinic acid has been used clinically for the treatment of dyslipidemia. Tryptamine derivatives have been studied for their effects on mood, cognition, and other neurological functions. Further studies are needed to characterize the compound's specific in vivo activities. |
| Enzyme Assay |
Non-cell-based assays for nicotredole include receptor binding assays using GPR109A or serotonin receptors. Radioligand binding assays can be used to assess the compound's affinity for these receptors. Enzyme assays may be used to assess effects on nicotinic acid-related metabolic pathways. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization.
|
| Cell Assay |
Cell-based assays for nicotredole use cell lines expressing GPR109A or serotonin receptors. Receptor activation can be assessed by measuring downstream signaling (e.g., cAMP inhibition for GPR109A). Serotonergic activity can be assessed by measuring intracellular calcium or other second messengers. Cell viability and cytotoxicity are assessed using standard assays.
|
| Animal Protocol |
In vivo studies of nicotredole are limited. Potential animal models include: dyslipidemia models for evaluating effects on lipid metabolism; and behavioral models for evaluating neurological effects. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
Nicotredole (Tryptamide) has a molecular formula of C₁₆H₁₅N₃O and a molecular weight of approximately 265.31 g/mol. It is a synthetic compound combining nicotinic acid and tryptamine moieties. The compound is soluble in organic solvents such as DMSO. It should be stored as a powder at -20°C for up to 3 years or in solvent at -80°C for 1 year. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for nicotredole are limited. As a research compound, its safety profile has not been fully characterized. Standard laboratory safety practices should be followed when handling this compound, including the use of personal protective equipment. It is intended for research use only.
|
| References |
[1]. Herman ZS, et, al. Basic pharmacological properties of a novel antiinflammatory drug tryptamide. Pol J Pharmacol Pharm. Nov-Dec 1987;39(6):729-36.
[2]. Szumiło H. Pharmacokinetics of tryptamide following oral and intraperitoneal administration in rats. Acta Pol Pharm. 1990;47(1-2):19-22. [3]. Kulig D, et, al. A comparison of anti-inflammatory, analgesic and ulcerogenic action of tryptamide, ibuprofen and piroxicam. Pol J Pharmacol Pharm. Nov-Dec 1987;39(6):769-72. |
| Additional Infomation |
Tryptamide is a small molecule drug. The molecular weight of a single isotope of nicotetradamide is 265.12 Da. (Structure can be found in the first source.)
Nicotredole (Tryptamide) is a synthetic compound that combines nicotinic acid (niacin) and tryptamine moieties. Nicotinic acid is a B vitamin (niacin) that plays a critical role in energy metabolism and is used clinically for the treatment of dyslipidemia. Tryptamine is a monoamine alkaloid with various biological effects, including interaction with serotonin receptors. The compound is used as a research chemical for studying the combined effects of nicotinic acid and tryptamine derivatives. It is for research use only. |
| Molecular Formula |
C16H15N3O
|
|---|---|
| Molecular Weight |
265.31
|
| Exact Mass |
265.121
|
| CAS # |
29876-14-0
|
| PubChem CID |
65768
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
588.4±35.0 °C at 760 mmHg
|
| Flash Point |
309.7±25.9 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.669
|
| LogP |
1.94
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
334
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=C([H])N=C([H])C([H])=C1[H])N([H])C([H])([H])C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12
|
| InChi Key |
ZDAZUJBASMCUAK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H15N3O/c20-16(13-4-3-8-17-10-13)18-9-7-12-11-19-15-6-2-1-5-14(12)15/h1-6,8,10-11,19H,7,9H2,(H,18,20)
|
| Chemical Name |
N-[2-(1H-indol-3-yl)ethyl]pyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (94.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.84 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7692 mL | 18.8459 mL | 37.6918 mL | |
| 5 mM | 0.7538 mL | 3.7692 mL | 7.5384 mL | |
| 10 mM | 0.3769 mL | 1.8846 mL | 3.7692 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
